Adaptive Biotechnologies logo
Adaptive Biotechnologies
ADPT | NASDAQ
Chart Builder DCF Calculator
$27.87
-$1.17 (-4.03%)
At close: Nov 16, 2026, 4:00 PM ET
$27.87
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Adaptive Biotechnologies Company Profile

Company profile explained

Company Profile

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

Key Executives

Name Position
Chad Robins Co-Founder, Chief Executive Officer & Chairman
Francis T. Lo Chief People Officer
Julie Rubinstein President & Chief Operating Officer
Kyle Piskel Vice President, Chief Financial Officer & Principal Accounting Officer
Christopher Carlson Founder
Clarice McCauley Head of Legal, Corporate Secretary, VP & Chief Compliance Officer
Karina Calzadilla VP of Investor Relations and FP&A
Mary Pat Lancelotta Senior Vice President, Global Market & Business Development
Sharon Benzeno Chief Commercial Officer of Immune Medicine
Susan Bobulsky Chief Commercial Officer of MRD

Latest SEC Filings

Date Type Title
Oct 29, 2026 4 Filing
Oct 26, 2026 4 Filing
Oct 21, 2026 4 Filing
Oct 16, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 08, 2026 4 Filing
Oct 08, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Sep 18, 2026 4 Filing
View All SEC Filings ➞
Adaptive Biotechnologies
Adaptive Biotechnologies logo
Country United States
IPO Date Jun 27, 2019
Industry Biotechnology
Sector Healthcare
Employees 624
CEO Chad Robins

Contact Details

1165 Eastlake Avenue East Seattle, Washington 98109 United States

Stock Details

Ticker Symbol ADPT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001478320
CUSIP Number 00650F109
ISIN Number US00650F1093
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.